Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported […]
March 2, 2020
Diagnostic Cytopathology 2020 February 20 [Link] Abd Own S, Höijer J, Hillerdahl G, Dobra K, Hjerpe A Abstract A conclusive diagnosis of malignant mesothelioma (MM) can be based on effusion cytology using the guidelines for the cytopathologic diagnosis of epithelioid and mixed-type MM. Briefly, the diagnosis is obtained when the mesothelial phenotype of malignant cells […]
February 20, 2020
Journal of Molecular Diagnostics 2020 February 6 [Link] Bruno R, Alì G, Poma AM, Proietti A, Libener R, Mariani N, Niccoli C, Chella A, Ribechini A, Grosso F, Fontanini G Abstract Pleural effusions are among the first clinical manifestations of malignant pleural mesothelioma (MPM) and often constitute the only available material for diagnosis. Although an […]
February 18, 2020
BMJ Case Reports 2020 January 2 [Link] Hinkamp CA, Dalal SN, Butt Y, Cabo Chan Abstract Malignant mesothelioma is an uncommon form of neoplastic transformation of the mesothelial cells that line the serosal surfaces of the body. It most commonly affects the pleura and is often associated with pleural effusions and pleural-based masses. The annual […]
January 15, 2020
Respiratory Medicine Case Reports 2019 November 21 [Link] Dalgleish AG, McLean E, Patel N, Rahman N Abstract A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own […]
December 13, 2019
Lung Cancer 2019 November 18 [Link] Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with dismal prognosis but variable course of disease. To support diagnosis and to risk stratify patients, more reliable biomarkers are warranted. Emerging evidence underlines a […]
December 10, 2019
Oncotarget 2019 November 5 [Link] Donnenberg AD, Luketich JD, Donnenberg VS Abstract INTRODUCTION: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to neoplasia in pleural effusion […]
November 29, 2019
Respiration 2019 October 25 [Link] Fortin M, Cabon E, Berbis J, Laroumagne S, Guinde J, Elharrar X, Dutau H, Astoul P Abstract BACKGROUND: Medical history, thoracentesis, and imaging features are usually the first steps in the investigation of a possible malignant pleural effusion (MPE). Unfortunately, the diagnostic yield of thoracentesis in this situation is suboptimal […]
November 4, 2019
Anticancer Research 2019 September [Link] Abstract AIM: This study evaluated the prognostic value of soluble mesothelin-related protein (SMRP) levels in pleural effusions (PE) from patients with pleural mesothelioma (MPM). PATIENTS AND METHODS: SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment. The […]
September 17, 2019
American Journal of Surgery 2019 June 23 [Link] Singh B, Singh G, Alzahrani N, Morris DL Abstract OBJECTIVES: To assess the impact of short and long term outcomes of diaphragm resection and repair in cyto-reductive surgery (CRS) and intra-peritoneal chemotherapy (IPC). METHODS: 1230 consecutive CRS/IPC procedures were performed between 1996 and 2018 in Sydney, Australia. […]
July 15, 2019